Back to news

Altimmune to Participate in the 9th Annual Evercore Healthcare Conference

Globe Newswire•19/11/2026•08:00 ET
0

Key Highlights

  • ➤Altimmune management to join Evercore Healthcare Conference fireside chat December 1, 2026
  • ➤Pemvidutide remains in late-stage development for metabolic dysfunction-associated steatohepatitis
  • ➤Pemvidutide showed robust results in the RECLAIM Phase 2 alcohol use disorder trial
  • ➤Pemvidutide is being studied in alcohol-associated liver disease

MORRISTOWN, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist, in serious liver diseases, today announced that management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026, at 3:25 p.m. ET.

A webcast of the fireside chat will be available via the Events section of the Altimmune website.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in